Research

Changes in Age-Related Mortality in Malignant Melanoma From 1999- 2022: A CDC Wonder Study


 

Background

Melanoma is one of the leading causes of solid tumor cancers. This study’s objective is to analyze temporal trends in melanoma-related mortality among age groups in the US before and during COVID-19. To date, no previous studies have analyzed year-to-year trends in melanoma mortality by age group using the CDC Wonder database. A 2011 analysis previously showed increasing death rates only among those over age 65 between 1992-2006.

Methods

The CDC Wonder database was used to collect data on melanoma-related mortality rates in the US from 1999-2022. Crude mortality rates per 100,000 and annual percentage change using Joinpoint regression were used to analyze yearly trends among age groups.

Results

From 1999 to 2022, overall mortality rate fell from 2.91 to 2.07, and mortality rates among all age groups decreased with the exception of those over age 85. Age 35-44 crude mortality rate decreased from 1.42 to .7. Age 45-54 crude mortality rate decreased from 3.2 to 1.51. Age 55-64 decreased from 5.6 to 3.61. Age 65-74 decreased from 9.91 to 7.79. Age 75-84 decreased from 15.44 to 15.43. Ages 85+ increased from 21.5 to 33.1. Notably, mortality among those age 75-85 decreased by only .01, and were increased across the timespan of 2000-2020.

Conclusions

These results show that there may be differences between age groups in how mortality due to melanoma of age groups has changed from 1992-2022. While overall mortality attributed to melanoma fell during this period, mortality in those over age 85 increased. Future studies should confirm these results with different data sets and further investigate the reasons for these disparities.

Recommended Reading

In Colorectal Cancer, Donating Half a Liver Could Save Lives
Federal Practitioner
Metastatic Prostate Cancer Presenting as Pleural and Pericardial Metastases: A Case Report and Literature Review
Federal Practitioner
Study Indicates Skin Cancer Risk Elevated Among Veterans
Federal Practitioner
Asynchronous Bilateral Breast Cancer in a Male Patient
Federal Practitioner
Do We Need More Screen Time? Patterns of Telehealth Utilization for Patients With Prostate Cancer in the Veterans Health Administration (VHA)
Federal Practitioner
Identifying Barriers in Germline Genetic Testing Referrals for Breast Cancer: A Single-Center Experience
Federal Practitioner
A Phase II Study With Androgen Deprivation Therapy and Up-Front Radiotherapy in High-Intermediate and High-Risk Prostate Cancer With Stereotactic Body Radiation Therapy to Pelvic Nodes and Concomitant Prostate Boost by Simultaneous Integrated Boost
Federal Practitioner
Data Elements Captured in Breast and Gynecologic Oncology System of Excellence Health Informatics Tool
Federal Practitioner
Implementation of an Intervention to Improve Efficiency and Accuracy of Data Entry into the Veterans Affairs Central Cancer Registry at the Lexington VA Healthcare System
Federal Practitioner
Geographical Trends in Malignant Melanoma from 1999-2022: A CDC Wonder Study
Federal Practitioner